Published in Eur Arch Psychiatry Clin Neurosci on February 18, 2011
Overexpression of Reelin prevents the manifestation of behavioral phenotypes related to schizophrenia and bipolar disorder. Neuropsychopharmacology (2011) 1.08
Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments. Neuropharmacology (2012) 1.00
The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: findings from the European Schizophrenia Cohort (EuroSC). Eur Arch Psychiatry Clin Neurosci (2012) 0.97
Chemokines in bipolar disorder: trait or state? Eur Arch Psychiatry Clin Neurosci (2012) 0.91
Lurasidone for the treatment of bipolar depression: an evidence-based review. Neuropsychiatr Dis Treat (2015) 0.85
Monocyte and lymphocyte activation in bipolar disorder: a new piece in the puzzle of immune dysfunction in mood disorders. Int J Neuropsychopharmacol (2014) 0.84
The impact of repeated manic episodes and executive dysfunction on work adjustment in bipolar disorder. Eur Arch Psychiatry Clin Neurosci (2013) 0.84
Quantitative Trait Locus and Brain Expression of HLA-DPA1 Offers Evidence of Shared Immune Alterations in Psychiatric Disorders. Microarrays (Basel) (2016) 0.76
Somatic Care with a Psychotic Disorder. Lower Somatic Health Care Utilization of Patients with a Psychotic Disorder Compared to Other Patient Groups and to Controls Without a Psychiatric Diagnosis. Adm Policy Ment Health (2016) 0.75
From generation of biomarkers to treatment and psychosocial aspects of psychosis. Eur Arch Psychiatry Clin Neurosci (2011) 0.75
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2005) 58.92
Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature (2009) 33.26
Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA (1990) 17.70
Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry (2007) 8.11
A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry (2007) 7.49
Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs (2005) 5.84
Causes of the excess mortality of schizophrenia. Br J Psychiatry (2000) 5.40
Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet (2003) 4.79
Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand (2007) 4.51
Size and burden of mental disorders in Europe--a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol (2005) 4.50
Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev (2008) 4.43
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord (2009) 3.56
Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry (2003) 3.54
The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry (2005) 3.53
Assessment of insight in psychosis. Am J Psychiatry (1993) 3.48
Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry (2005) 3.33
Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord (2002) 3.28
Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk. Mol Psychiatry (2008) 3.01
The 'continuum of psychosis': scientifically unproven and clinically impractical. Br J Psychiatry (2010) 2.86
Medical comorbidity in women and men with schizophrenia: a population-based controlled study. J Gen Intern Med (2006) 2.79
Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry (2007) 2.78
Schizophrenia and violence: systematic review and meta-analysis. PLoS Med (2009) 2.74
Psychiatric comorbidities and schizophrenia. Schizophr Bull (2008) 2.69
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry (2008) 2.64
The prediction of criminal and violent recidivism among mentally disordered offenders: a meta-analysis. Psychol Bull (1998) 2.60
A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry (2001) 2.58
The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychol Med (1997) 2.57
Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry (1995) 2.53
Psychiatric genetics: progress amid controversy. Nat Rev Genet (2008) 2.51
The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord (1998) 2.47
Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry (2001) 2.38
The increasing medical burden in bipolar disorder. JAMA (2005) 2.33
Antidepressants in bipolar disorder: the case for caution. Bipolar Disord (2003) 2.27
Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry (2008) 2.20
Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents. Am J Psychiatry (2000) 2.16
Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry (2004) 2.14
Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord (2005) 2.12
Rare copy number variants: a point of rarity in genetic risk for bipolar disorder and schizophrenia. Arch Gen Psychiatry (2010) 2.11
Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry (2005) 2.00
Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry (2005) 1.99
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry (2005) 1.98
Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med (2005) 1.97
Evolution in health and medicine Sackler colloquium: Comparative genomics of autism and schizophrenia. Proc Natl Acad Sci U S A (2009) 1.95
Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry (2007) 1.94
Depression status, medical comorbidity and resource costs. Evidence from an international study of major depression in primary care (LIDO). Br J Psychiatry (2003) 1.91
The prevalence and co-morbidity of subthreshold psychiatric conditions. Psychol Med (2004) 1.89
Evidence for shared susceptibility in bipolar disorder and schizophrenia. Am J Med Genet C Semin Med Genet (2003) 1.80
Psychotic depression and mortality. Am J Psychiatry (2003) 1.78
Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry (2003) 1.77
Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv (2009) 1.77
Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry (2003) 1.73
Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry (2002) 1.71
Genetics of affective (mood) disorders. Eur J Hum Genet (2006) 1.70
Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial. J Clin Psychiatry (2008) 1.70
Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry (2006) 1.70
Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry (2006) 1.61
Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry (2009) 1.60
Suicide risk in bipolar patients: the role of co-morbid substance use disorders. Bipolar Disord (2003) 1.59
Meta-analytic evidence for familial coaggregation of schizophrenia and bipolar disorder. Arch Gen Psychiatry (2009) 1.56
Patients with multiple sclerosis presenting to psychiatric hospitals. J Clin Psychiatry (1995) 1.52
Medical comorbidity in women and men with bipolar disorders: a population-based controlled study. Psychosom Med (2006) 1.50
Lifetime co-morbidities between social phobia and mood disorders in the US National Comorbidity Survey. Psychol Med (1999) 1.50
The effects of undertreated chronic medical illnesses in patients with severe mental disorders. J Clin Psychiatry (2009) 1.46
Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry (2006) 1.45
The thyroid-brain interaction in thyroid disorders and mood disorders. J Neuroendocrinol (2008) 1.43
Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. J Clin Psychiatry (2004) 1.42
Phenotype of schizophrenia: a review and formulation. Mol Psychiatry (2005) 1.41
The metabolic syndrome and schizophrenia. Acta Psychiatr Scand (2009) 1.40
Influence of comorbid alcohol and psychiatric disorders on utilization of mental health services in the National Comorbidity Survey. Am J Psychiatry (1999) 1.39
Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord (2002) 1.37
Suicide and schizophrenia. J Psychopharmacol (2001) 1.34
Gene-environment interplay between cannabis and psychosis. Schizophr Bull (2008) 1.34
Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry (2002) 1.34
Importance of psychotic features to long-term course in major depressive disorder. Am J Psychiatry (1996) 1.33
Tobacco smoking behaviors in bipolar disorder: a comparison of the general population, schizophrenia, and major depression. Bipolar Disord (2009) 1.32
Imbalanced genomic imprinting in brain development: an evolutionary basis for the aetiology of autism. J Evol Biol (2006) 1.31
Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord (2008) 1.30
Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res (2001) 1.29
Nosologomania: DSM & Karl Jaspers' critique of Kraepelin. Philos Ethics Humanit Med (2009) 1.28
Clinical utility: a prerequisite for the adoption of a dimensional approach in DSM. J Abnorm Psychol (2005) 1.28
Bipolar disorder, schizoaffective disorder, and schizophrenia overlap: a new comorbidity index. J Clin Psychiatry (2009) 1.25
From Kraepelin to Kretschmer leavened by Schneider: thextransition from categories of psychosis to dimensions of variation intrinsic to homo sapiens. Arch Gen Psychiatry (1998) 1.24
Increased risk of developing dementia in patients with major affective disorders compared to patients with other medical illnesses. J Affect Disord (2003) 1.23
Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry (2005) 1.22
How and why genetic linkage has not solved the problem of psychosis: review and hypothesis. Am J Psychiatry (2007) 1.21
Relationships between obsessive-compulsive symptomatology and severity of psychosis in schizophrenia: a systematic review and meta-analysis. J Clin Psychiatry (2008) 1.20
Schizophrenia and sudden cardiac death: a review. Nord J Psychiatry (2008) 1.19
Gender differences in bipolar disorder. Psychiatr Clin North Am (2003) 1.18
The validity of major depression with psychotic features based on a community study. Arch Gen Psychiatry (1991) 1.17
Medical comorbidity in a bipolar outpatient clinical population. Neuropsychopharmacology (2005) 1.17
Medical comorbidity in psychiatric inpatients: relation to clinical outcomes and hospital length of stay. Psychosomatics (2002) 1.16
The current status of tardive dyskinesia. Aust N Z J Psychiatry (2000) 1.16
Delusional and nondelusional unipolar depression: further evidence for distinct subtypes. Am J Psychiatry (1981) 1.15
Substance use disorders in schizophrenia--clinical implications of comorbidity. Schizophr Bull (2009) 1.14
The prevalence and impact of migraine headache in bipolar disorder: results from the Canadian Community Health Survey. Headache (2006) 1.13
The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov (2009) 1.12
Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression. Psychiatry Res (2004) 1.12
Course of psychiatric and substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitalization. J Clin Psychiatry (1998) 1.11
Risk of stillbirth and neonatal death linked with maternal mental illness: a national cohort study. Arch Dis Child Fetal Neonatal Ed (2008) 1.09
The effect of comorbid substance use disorders on the course of bipolar disorder: a review. Harv Rev Psychiatry (1999) 1.09
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull (2003) 4.13
A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry (2003) 3.77
Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry (2004) 2.31
Autosomal dominant frontotemporal lobar degeneration due to the C9ORF72 hexanucleotide repeat expansion: late-onset psychotic clinical presentation. Biol Psychiatry (2013) 1.58
Clinical trials design lessons from the CATIE study. Am J Psychiatry (2009) 1.32
Validation of the Italian version of the "Mood Disorder Questionnaire" for the screening of bipolar disorders. Clin Pract Epidemiol Ment Health (2005) 1.29
What have we learned about trial design from NIMH-funded pragmatic trials? Neuropsychopharmacology (2010) 1.17
Duration of untreated illness and suicide in bipolar disorder: a naturalistic study. Eur Arch Psychiatry Clin Neurosci (2009) 1.07
Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv (2006) 1.05
Selective DNA methylation of BDNF promoter in bipolar disorder: differences among patients with BDI and BDII. Neuropsychopharmacology (2012) 1.04
Insight in first-episode psychosis. Psychol Med (2006) 0.94
Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol (2006) 0.93
Age at onset and latency to treatment (duration of untreated illness) in patients with mood and anxiety disorders: a naturalistic study. Int Clin Psychopharmacol (2010) 0.89
A relationship between oxytocin and anxiety of romantic attachment. Clin Pract Epidemiol Ment Health (2006) 0.89
Can long-term outcomes be improved by shortening the duration of untreated illness in psychiatric disorders? A conceptual framework. Psychopathology (2012) 0.89
The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. J Clin Psychiatry (2008) 0.88
Mood stabilizers for patients with bipolar disorder: the state of the art. Expert Rev Neurother (2011) 0.88
Neuropsychobiological aspects, comorbidity patterns and dimensional models in borderline personality disorder. Neuropsychobiology (2010) 0.86
Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. J Clin Psychopharmacol (2007) 0.85
Characteristics of eating disorder patients without a drive for thinness. Int J Eat Disord (2002) 0.85
Schizophrenia and binge-eating disorders. J Clin Psychiatry (2004) 0.84
The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol (2007) 0.84
Relationship between bipolar illness and binge-eating disorders. Psychiatry Res (2005) 0.83
Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease. PLoS One (2012) 0.83
Predictors of clinical outcome in schizophrenic patients responding to clozapine. J Clin Psychopharmacol (2003) 0.83
Designing outcome studies to determine efficacy and safety of antipsychotics for 'real world' treatment of schizophrenia. Int J Neuropsychopharmacol (2010) 0.83
Characterizing impulsivity profile in patients with obsessive-compulsive disorder. Int J Psychiatry Clin Pract (2013) 0.83
Issues that may determine the outcome of antipsychotic trials: industry sponsorship and extrapyramidal side effect. Neuropsychopharmacology (2007) 0.82
Intravenous augmentative citalopram versus clomipramine in partial/nonresponder depressed patients: a short-term, low dose, randomized, placebo-controlled study. J Clin Psychopharmacol (2008) 0.82
Alterations of the dopamine transporter in resting lymphocytes of patients with different psychotic disorders. Psychiatry Res (2009) 0.81
Assessing working memory via N-back task in euthymic bipolar I disorder patients: a review of functional magnetic resonance imaging studies. Neuropsychobiology (2013) 0.81
Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharmacol (2011) 0.81
Progranulin gene variability and plasma levels in bipolar disorder and schizophrenia. PLoS One (2012) 0.80
Efficacy and safety of transcranial direct current stimulation in major depression. Biol Psychiatry (2011) 0.80
Is duration of illness really influencing outcome in major psychoses? Nord J Psychiatry (2015) 0.79
The impact of brief depressive episodes on the outcome of bipolar disorder and major depressive disorder: a 1-year prospective study. J Affect Disord (2011) 0.79
Is the combination of a mood stabilizer plus an antipsychotic more effective than mono-therapies in long-term treatment of bipolar disorder? A systematic review. J Affect Disord (2013) 0.79
Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study. J Psychopharmacol (2005) 0.79
Decreased density of peripheral benzodiazepine receptors in psychiatric patients after a suicide attempt. Life Sci (2005) 0.79
Epigenetic modulation of BDNF gene in patients with major depressive disorder. Biol Psychiatry (2012) 0.78
Progranulin gene variability influences the risk for bipolar I disorder, but not bipolar II disorder. Bipolar Disord (2014) 0.78
Pain and psychiatry: a critical analysis and pharmacological review. Clin Pract Epidemiol Ment Health (2006) 0.78
Binding of 3H-WIN-35,428 and 125I-RTI-121 to human platelet membranes. Neurochem Res (2006) 0.78
Psychiatric conditions in cosmetic surgery patients. Facial Plast Surg (2006) 0.78
Insight in body dysmorphic disorder with and without comorbid obsessive-compulsive disorder. CNS Spectr (2006) 0.78
Short-term intravenous citalopram augmentation in partial/nonresponders with major depression: a randomized placebo-controlled study. Int Clin Psychopharmacol (2008) 0.77
[Understanding the role of the duration of untreated illness in psychiatric disorders: a narrative review]. Riv Psichiatr (2010) 0.77
Deep Brain Stimulation device removal after scar picking behaviors in a patient with treatment-resistant obsessive compulsive disorder. Brain Stimul (2012) 0.77
Presence of D4 dopamine receptors in human prefrontal cortex: a postmortem study. Rev Bras Psiquiatr (2007) 0.77
Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. Schizophr Res (2013) 0.77
Neuropsychology, social cognition and global functioning among bipolar, schizophrenic patients and healthy controls: preliminary data. Front Hum Neurosci (2013) 0.77
Teaching psychopharmacology: what works and what doesn't. J Clin Psychopharmacol (2008) 0.77
Survival analysis with clustered observations of orthodontic brackets. Stat Med (2009) 0.76
Duration of untreated illness and duration of illness in anxiety disorders: assessment and influence on outcome. Mod Trends Pharmacopsychiatri (2013) 0.76
Drug and psychosocial curricula for psychiatry residents for treatment of schizophrenia: part I. Psychiatr Serv (2004) 0.76
Central nervous system drug development, basic, and clinical research: thinking outside the box. J Clin Psychopharmacol (2011) 0.76
Conflict of interest, journal review, and publication policy. Neuropsychopharmacology (2008) 0.76
Effectiveness of risperidone in psychogenic stiff neck. CNS Spectr (2005) 0.76
C9ORF72 hexanucleotide repeat expansion as a rare cause of bipolar disorder. Bipolar Disord (2013) 0.76
Prevalence and disability of comorbid social phobia and obsessive-compulsive disorder in patients with panic disorder and generalized anxiety disorder. Int J Psychiatry Clin Pract (2014) 0.76
Aripiprazole as a dopamine partial agonist: positive and negative effects. J Clin Psychopharmacol (2006) 0.76
CATIE findings revisited. Psychiatr Serv (2009) 0.75
Duloxetine in affective disorders: a naturalistic study on psychiatric and medical comorbidity, use in association and tolerability across different age groups. Clin Pract Epidemiol Ment Health (2012) 0.75
Neuroimaging procedures and related acquisitions in bipolar disorder: state of the art. Riv Psichiatr (2014) 0.75
Changes in peripheral benzodiazepine receptors in patients with bipolar disorder. Neuropsychiatr Dis Treat (2005) 0.75
Topiramate plus citalopram in the treatment of Compulsive-Impulsive Sexual Behaviors. Clin Pract Epidemiol Ment Health (2006) 0.75
Neurodevelopmental Versus Neurodegenerative Model of Schizophrenia and Bipolar Disorder: Comparison with Physiological Brain Development and Aging. Psychiatr Danub (2017) 0.75
Teaching the Teachers of Clinical Psychopharmacology. Acad Psychiatry (2014) 0.75
Which factors influence onset and latency to treatment in generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder? Int Clin Psychopharmacol (2016) 0.75
The Use of Zonisamide for the Treatment of Psychiatric Disorders: A Systematic Review. Clin Neuropharmacol (2017) 0.75
Tolerability and use in co-administration of pregabalin in affective patients: a 6-month prospective naturalistic study. Expert Opin Drug Saf (2012) 0.75
Intensive Design to Reinvigorate Psychiatric Drug Development. J Clin Psychopharmacol (2015) 0.75
Family therapy: the neglected core competence. Acad Psychiatry (2012) 0.75
Family Problems and Sports Performance: The Role of Couple's Therapy in Treating Athletes and Their Families. Phys Sportsmed (2005) 0.75
Health literacy and the pharmacological treatment of anxiety disorders: a systematic review. Hum Psychopharmacol (2014) 0.75
[Should we continue to use benzodiazepines in clinical practice?]. Recenti Prog Med (2015) 0.75
Treating schizophrenia with comorbid depressive or demoralization symptoms. J Clin Psychiatry (2008) 0.75
Psychopharmacology Training for Psychiatry Residents: A Pilot Iterative Quality Improvement Project. J Clin Psychopharmacol (2017) 0.75
Concomitant psychotropic medication use during treatment of schizophrenia patients: longitudinal results from the CATIE study. Clin Schizophr Relat Psychoses (2011) 0.75
The challenge of teaching psychopharmacology and improving clinical practice. J Clin Psychopharmacol (2005) 0.75
Sex Steroids and Major Psychoses: Which Role for DHEA-S and Progesterone. Neuropsychobiology (2016) 0.75
[Gambling: an Italian record that it would be better not to have]. Recenti Prog Med (2013) 0.75